BioCentury | Sep 28, 2015
Company News

University of Minnesota, Oxis deal

Two researchers at the university granted Oxis exclusive, worldwide rights to develop and commercialize DT2219ARL . The researchers will receive an upfront payment and are eligible for milestones, plus royalties. The product is a bispecific single-chain...
BioCentury | Sep 28, 2015
Company News

University of Minnesota, Oxis deal

Two researchers at the university granted Oxis exclusive, worldwide rights to develop and commercialize DT2219ARL . The researchers will receive an upfront payment and are eligible for milestones, plus royalties. The product is a bispecific single-chain...
BioCentury | Feb 13, 2014
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Interferon-b (IFNB; IFN-b) Mouse studies suggest directly coupling antibodies to IFN-b could help treat cancer. In multiple mouse models of...
BioCentury | Apr 16, 2012
Clinical News

Immunomedics preclinical data

In an in vitro soft agar growth assay, Hex-hR1 significantly inhibited growth of 2 different RCC cell lines vs. controls (p<0.038 and p<0.0022, respectively). Data were presented at the American Association of Cancer Research meeting...
BioCentury | Mar 5, 2007
Company News

Arius, Fusion Antibodies deal

...ARI to treat cancer. Financial terms were not disclosed. Arius Research Inc. (TSX:ARI), Toronto, Ontario Fusion Antibodies Ltd....
BioCentury | Dec 18, 2006
Company News

Abcam, Fusion Antibodies sales and marketing update

...on ABC's product sales; further financial terms were not disclosed. Abcam plc (LSE:ABC), Cambridge, U.K. Fusion Antibodies Ltd....
BioCentury | Nov 20, 2006
Company News

Fusion Antibodies management update

Fusion Antibodies Ltd. , Belfast, U.K. Business: Antibodies Hired: Simon Douglas as CEO, formerly CEO of DNA Research Innovations Ltd. ; he replaces Jim Johnston, who remains as CSO WIR Staff...
BioCentury | Aug 29, 1994
Clinical News

Bristol-Myers Squibb preclinical data

BMY's Pharmaceutical Research Institute in Seattle published successful treatment of the disease in a mouse model, using a protein that interrupts a signal needed to activate antigen-specific T cells. The fusion antibody blocked formation of...
Items per page:
1 - 8 of 8
BioCentury | Sep 28, 2015
Company News

University of Minnesota, Oxis deal

Two researchers at the university granted Oxis exclusive, worldwide rights to develop and commercialize DT2219ARL . The researchers will receive an upfront payment and are eligible for milestones, plus royalties. The product is a bispecific single-chain...
BioCentury | Sep 28, 2015
Company News

University of Minnesota, Oxis deal

Two researchers at the university granted Oxis exclusive, worldwide rights to develop and commercialize DT2219ARL . The researchers will receive an upfront payment and are eligible for milestones, plus royalties. The product is a bispecific single-chain...
BioCentury | Feb 13, 2014
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Interferon-b (IFNB; IFN-b) Mouse studies suggest directly coupling antibodies to IFN-b could help treat cancer. In multiple mouse models of...
BioCentury | Apr 16, 2012
Clinical News

Immunomedics preclinical data

In an in vitro soft agar growth assay, Hex-hR1 significantly inhibited growth of 2 different RCC cell lines vs. controls (p<0.038 and p<0.0022, respectively). Data were presented at the American Association of Cancer Research meeting...
BioCentury | Mar 5, 2007
Company News

Arius, Fusion Antibodies deal

...ARI to treat cancer. Financial terms were not disclosed. Arius Research Inc. (TSX:ARI), Toronto, Ontario Fusion Antibodies Ltd....
BioCentury | Dec 18, 2006
Company News

Abcam, Fusion Antibodies sales and marketing update

...on ABC's product sales; further financial terms were not disclosed. Abcam plc (LSE:ABC), Cambridge, U.K. Fusion Antibodies Ltd....
BioCentury | Nov 20, 2006
Company News

Fusion Antibodies management update

Fusion Antibodies Ltd. , Belfast, U.K. Business: Antibodies Hired: Simon Douglas as CEO, formerly CEO of DNA Research Innovations Ltd. ; he replaces Jim Johnston, who remains as CSO WIR Staff...
BioCentury | Aug 29, 1994
Clinical News

Bristol-Myers Squibb preclinical data

BMY's Pharmaceutical Research Institute in Seattle published successful treatment of the disease in a mouse model, using a protein that interrupts a signal needed to activate antigen-specific T cells. The fusion antibody blocked formation of...
Items per page:
1 - 8 of 8